- Home
- SRBK vs MIST Comparison
SRBK vs MIST Comparison
Compare SRBK & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRBK
- MIST
- Stock Information
- Founded
- SRBK 1887
- MIST 2003
- Country
- SRBK United States
- MIST Canada
- Employees
- SRBK N/A
- MIST N/A
- Industry
- SRBK
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- SRBK
- MIST Health Care
- Exchange
- SRBK Nasdaq
- MIST Nasdaq
- Market Cap
- SRBK 109.9M
- MIST 89.8M
- IPO Year
- SRBK N/A
- MIST N/A
- Fundamental
- Price
- SRBK $12.87
- MIST $1.71
- Analyst Decision
- SRBK
- MIST Strong Buy
- Analyst Count
- SRBK 0
- MIST 2
- Target Price
- SRBK N/A
- MIST $7.50
- AVG Volume (30 Days)
- SRBK 69.5K
- MIST 659.9K
- Earning Date
- SRBK 07-25-2025
- MIST 08-07-2025
- Dividend Yield
- SRBK 0.39%
- MIST N/A
- EPS Growth
- SRBK N/A
- MIST N/A
- EPS
- SRBK N/A
- MIST N/A
- Revenue
- SRBK $27,988,000.00
- MIST N/A
- Revenue This Year
- SRBK N/A
- MIST N/A
- Revenue Next Year
- SRBK N/A
- MIST N/A
- P/E Ratio
- SRBK N/A
- MIST N/A
- Revenue Growth
- SRBK 23.80
- MIST N/A
- 52 Week Low
- SRBK $9.12
- MIST $0.63
- 52 Week High
- SRBK $13.65
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- SRBK 51.51
- MIST 60.15
- Support Level
- SRBK $12.90
- MIST $1.67
- Resistance Level
- SRBK $13.08
- MIST $1.80
- Average True Range (ATR)
- SRBK 0.25
- MIST 0.08
- MACD
- SRBK -0.01
- MIST -0.01
- Stochastic Oscillator
- SRBK 61.67
- MIST 43.24
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).